Hsingching Hsu v. Puma Biotechnology, Inc., 213 F. Supp. 3d 1275

Background

Plaintiffs (Norfolk County Council and other investors) filed a putative securities class action under §10(b) and SEC Rule 10b-5 and §20(a) alleging Puma Biotechnology and two executives made false or misleading statements about results of the ExteNET clinical trial for neratinib (PB272).
Core alleged misstatements concerned (1) reported disease-free survival (DFS) rates and the claimed “33% improvement” and (2) representations that Kaplan–Meier survival curves were separating (indicating increasing benefit over time) when plaintiffs allege they were narrowing.
Key documents at issue include a July 2014 press release, earnings/analyst call transcripts, ASCO slides, SEC filings, and various analyst reports; timing of statements is tied to Puma’s later public offering and executives’ performance-based compensation.
Puma moved to dismiss under Rules 9(b) and 12(b)(6) and the PSLRA, arguing plaintiffs failed to plead falsity, scienter, and sufficiently particularized allegations against each defendant; Puma also submitted numerous extrinsic exhibits and requests for judicial notice.
The court analyzed the appropriate use of judicial notice and incorporation-by-reference doctrines, declining to take notice of several exhibits (analyst reports, certain web pages) but accepting others and the plaintiffs’ pleaded facts as true for purposes of the motion.
Holding: The Court denied the motion to dismiss, finding plaintiffs adequately pleaded falsity and scienter (albeit narrowly) and satisfied PSLRA/Rule 9(b) pleading requirements to proceed to discovery.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Falsity of DFS statements	Press release and call statements (e.g., "33% improvement", specific DFS rates/estimates, claims curves were separating) contradicted by actual trial numbers and contemporaneous data	Statements are accurate when viewed using hazard ratios or other proper statistical measures; some quotes were analyst conjecture or taken out of context	Court: Plaintiffs pleaded falsity sufficiently to survive dismissal; defendants’ statistical defenses are factual disputes for later stages
Kaplan–Meier/curve separation	Executives represented curves were "continuing to separate," misleading about trend when curves allegedly narrowed	Statements were nonactionable or innocuous, or based on different data/interpretation	Court: Allegations adequate to plausibly show misleading trend statements; context and credibility of interpretations are matters for discovery
Scienter (intent or deliberate recklessness)	Contemporaneous internal data/transcripts and timing (statements pre-sale; public offering; executives’ incentive comp) support strong inference of scienter	No motive or cogent facts showing defendants knew statements were false; alternative innocuous explanations more compelling	Court: Allegations, taken together, give at least an equally compelling inference of scienter as the opposite; pleads scienter adequately under PSLRA (narrowly)
Use of extrinsic materials (judicial notice / incorporation by reference)	Plaintiffs opposed taking notice of many exhibits and challenged authenticity/timing; urged court to limit extrinsic material	Puma sought judicial notice/incorporation for many exhibits to show market knowledge and to defeat pleading	Court: Carefully limited; accepted some exhibits (conference transcript, certain slides) for limited purposes, denied notice for analyst reports and certain web pages, and cautioned against overuse of these doctrines on a 12(b)(6) motion

Key Cases Cited

Bell Atl. Corp. v. Twombly, 550 U.S. 544 (plausibility pleading standard)
Ashcroft v. Iqbal, 556 U.S. 662 (pleading must permit reasonable inference of liability)
In re Rigel Pharm., Inc. Sec. Litig., 697 F.3d 869 (PSLRA and Rule 9(b) heightened pleading in securities cases)
In re Daou Sys., Inc., 411 F.3d 1006 (falsity and scienter often analyzed together)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (strong-inference test for scienter)
Metzler Inv. GMBH v. Corinthian Colleges, Inc., 540 F.3d 1049 (PSLRA falsity pleading requirements)
Siracusano v. Matrixx Initiatives, Inc., 585 F.3d 1167 (scienter: deliberate recklessness standard)
Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981 (scienter pleading guidance)
Nursing Home Pension Fund v. Oracle Corp., 380 F.3d 1226 (contemporaneous data can show falsity/scienter)
Kleinman v. Elan Corp., 706 F.3d 145 (distinguished by court on facts regarding omissions vs. affirmative falsehoods)
Hal Roach Studios, Inc. v. Richard Feiner & Co., 896 F.2d 1542 (courts generally limited to complaint on 12(b)(6))
United States v. Ritchie, 342 F.3d 903 (incorporation-by-reference and judicial notice principles)